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Erratum
In the March issue of BBMT the article by Drs. Lamb and Lopez (T cells: a new frontier for immunotherapy?
Biol Blood Marrow Transplant. 2005;11:161-168) included an editing error. The phrase “guanosine mono-
phosphate” was inadvertently inserted in place of “good manufacturing product”. The correct passage is as
follows: “Techniques are currently being developed for good manufacturing product–compatible clinical
scale ex vivo expansion of T cells. The first clinical trials are expected within the next 6 to 12 months.”
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